ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 219 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q3 2023. The put-call ratio across all filers is 0.74 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2016 | $118,083,000 | +13.1% | 1,679,460 | +14.2% | 0.02% | +4.8% |
| Q3 2016 | $104,365,000 | +53.4% | 1,471,171 | +5.8% | 0.02% | +40.0% |
| Q2 2016 | $68,033,000 | -25.5% | 1,390,985 | -3.6% | 0.02% | -28.6% |
| Q1 2016 | $91,347,000 | -42.6% | 1,442,851 | +1.6% | 0.02% | -43.2% |
| Q4 2015 | $159,235,000 | +11.5% | 1,419,462 | -4.3% | 0.04% | 0.0% |
| Q3 2015 | $142,864,000 | +6.0% | 1,483,381 | +12.7% | 0.04% | +15.6% |
| Q2 2015 | $134,793,000 | +241.8% | 1,316,464 | +107.3% | 0.03% | +255.6% |
| Q1 2015 | $39,431,000 | +62.8% | 635,055 | +15.1% | 0.01% | +50.0% |
| Q4 2014 | $24,219,000 | +183.2% | 551,945 | +265.3% | 0.01% | +200.0% |
| Q3 2014 | $8,553,000 | +29.1% | 151,106 | +2.4% | 0.00% | 0.0% |
| Q2 2014 | $6,624,000 | -17.7% | 147,569 | -10.4% | 0.00% | 0.0% |
| Q1 2014 | $8,049,000 | – | 164,642 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| First Light Asset Management, LLC | 213,887 | $29,608,000 | 2.19% |
| Rock Springs Capital Management LP | 566,500 | $78,421,000 | 1.66% |
| FEDERATED HERMES, INC. | 4,280,528 | $592,554,000 | 1.21% |
| AtonRa Partners | 17,646 | $2,443,000 | 1.20% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 218,390 | $30,232,000 | 1.05% |
| EMERALD ADVISERS, LLC | 226,875 | $31,406,000 | 1.04% |
| Atika Capital Management LLC | 89,000 | $12,319,000 | 0.96% |
| Capital Impact Advisors, LLC | 25,582 | $3,541,000 | 0.87% |
| JGP Global Gestao de Recursos Ltda. | 1,586 | $220,000 | 0.83% |
| CAPITAL INTERNATIONAL LTD /CA/ | 79,742 | $11,039,000 | 0.64% |